• INCLUSION CRITERIA:

Inclusion Criteria for all groups

1. All subjects: Minimum age of 2 enriches for patients that have active AD and are statistically less likely to resolve during this longitudinal study. Maximum age of 40 is to reduce chance of recruiting patients with age-related changes in skin.
2. All subjects: Must have a primary care professional who will continue care/evaluation in tandem with the protocol to whom information and recommendations can be communicated.

Inclusion Criteria for Group 1: Healthy Volunteers

1. Adult males or females WITHOUT asthma or allergic rhinitis aged 18-40.
2. Subset of males or females 2 - 40 years of age who MAY have asthma or allergic rhinitis, from whom MRSA isolates will be obtained.

Inclusion Criteria for Group 3: Age-Matched Controls

1. Males or females 2- 18 years of age.
2. Interval visits and age of controls must match those of enrolled AD patients.

Inclusion Criteria for Groups 2, 4, 5 & 6: AD/HIES/WAS/DOCK8 atients (unless specified otherwise)

1. AD patients: Diagnosis of atopic dermatitis on the basis of the criteria defined by UK Working Party's Diagnostic Criteria for Atopic Dermatitis. (Reference: Williams HC, Burney PG, Pembroke AC, et al: The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 131:406-16, 1994). Included in attachments.
2. AD patients: SCORAD (SCORing Atopic Dermatitis) score of greater than or equal to 25 indicating AD severity of moderate to severe. Included in appendix. (Reference: Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the Included in attachments.
3. AD patients: At least one antecubital (or popliteal) fossae must be affected at the time of enrollment to serve as a target site.
4. HIES, WAS or DOCK8 patients: Must have mutation-proven diagnosis, with or without eczematous dermatitis.

EXCLUSION CRITERIA:

Exclusion Criteria for all groups:

1. Any subjects with unstable or uncontrolled medical conditions. Individual determinations will be made at the discretion of the medical investigator.
2. Any subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants < 7 days or 5 half-lives (whichever is the longer time period) of initiating this protocol.
3. Any subjects who have cancer, and are currently or have previously received treatment with chemotherapy or radiation for treatment of malignancies within the previous 6 months.
4. Any subject with a history of bone marrow transplant or gene therapy.

Exclusion Criteria specific for groups 2, 4, 5 & 6: AD/HIES/WAS/DOCK8 patients (unless specified otherwise):

1. AD patients: Subjects who are unable to remain off systemic (oral) antibiotics or systemic (oral) steroids for at least 7 days prior to skin sample collection. Subjects who are unable to temporarily discontinue use of topical steroids or calcineurin inhibitors for >= 7 days to small areas of skin intended for sampling. (Topical therapies/emollients for AD may be continued to non-adjacent, non-target sites.)
2. AD patients: Subjects with underlying immunodeficiency, either as primary disease or secondary to treatment.
3. WAS/HIES/DOCK8 patients: unable to remain off topical steroids and emollients for preferably 7 days but at least 24 hours prior to skin sampling. HIES/WAS/DOCK8 patients will not be taken off their systemic (oral) antibiotics or systemic (oral) steroids. If unable to withhold topical therapies/emollients, all patients may continue application to non-adjacent, non-target sampling sites.)

Exclusion Criteria specific for Groups 1 & 3: Healthy Volunteers and Age-Matched Controls (In addition to the general exclusion criteria listed above for all groups unless specified otherwise):

1. Subjects with underlying immunodeficiency, either as primary disease or secondary to treatment.
2. Subject with other documented chronic dermatologic disease, such as AD or psoriasis, that may interfere with evaluation of the cutaneous microbiome. Common transient conditions, such as acne, are permissible.
3. Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals, in order to minimize potential ascertainment bias. (Certain pathogens such as Staphylococcus aureus and multi-drug resistant organisms are disproportionately associated with delivery of healthcare.)
4. Subjects with asthma or allergic rhinitis, except for the subset of Group 1 healthy volunteers designated as those undergoing sampling for MRSA isolates.
5. Children with past or ongoing parasitic infection.
6. Children who immigrated to the U.S. within the last 5 years
7. Any subject with a chronic disease requiring treatment. Individual determinations will be made at the discretion of the medical investigator.